Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. Through its unparalleled diagnostics and drug development capabilities, company provides insights and accelerates innovations to improve health and improve lives. With more than 70,000 employees, Labcorp serves clients in more than 100 countries. Labcorp reported revenue of $14 billion in FY2020.
Company profile
Ticker
LH
Exchange
Website
CEO
David King
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Quest Diagnostics • Akumin • Radnet • Burning Rock Biotech • Guardant Health • Genomic Health • Invitae • Natera • Enzo Biochem • Centogene ...
Former names
NATIONAL HEALTH LABORATORIES HOLDINGS INC
SEC CIK
Corporate docs
Subsidiaries
1957285 Ontario Inc. • 2089729 Ontario, Inc. • 2248848 Ontario Inc. • 3065619 Nova Scotia Company • 3257959 Nova Scotia Company • 896988 Ontario Limited • 9279-3280 Quebec Inc. • Accupath Diagnostic Laboratories, Inc. • Beacon Laboratory Benefit Solutions, Inc. • CannAmm GP Inc. ...
IRS number
133757370
LH stock data
News
BD, Labcorp Collaborate To Develop Flow Cytometry-Based Companion Diagnostics For Matching Patients Tith Treatments
9 Aug 22
Airbnb To $145? Here Are 5 Other Price Target Changes For Monday
1 Aug 22
Credit Suisse Maintains Outperform on Laboratory Corp, Lowers Price Target to $308
1 Aug 22
Where Laboratory Corp Stands With Analysts
29 Jul 22
Mizuho Maintains Buy on Laboratory Corp, Lowers Price Target to $296
29 Jul 22
Press releases
BD, Labcorp Collaborate to Develop Flow Cytometry-Based Companion Diagnostics for Matching Patients with Treatments
9 Aug 22
Monkeypox Plays Jockey For Position This Week
8 Aug 22
Labcorp Announces 2022 Second Quarter Results
28 Jul 22
Labcorp to Spin Off Clinical Development Business
28 Jul 22
Labcorp Earns Top Score on 2022 Disability Equality Index
22 Jul 22
Analyst ratings and price targets
Current price
Average target
$301.33
Low target
$296.00
High target
$308.00
Credit Suisse
Maintains
$308.00
Mizuho
Maintains
$296.00
Morgan Stanley
Maintains
$300.00
Calendar
1 Aug 22
12 Aug 22
31 Dec 22
Financial summary
| Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 1.07B | 1.07B | 1.07B | 1.07B | 1.07B | 1.07B |
| Cash burn (monthly) | 54.9M | 74.53M | (no burn) | (no burn) | (no burn) | (no burn) |
| Cash used (since last report) | 79.51M | 107.95M | n/a | n/a | n/a | n/a |
| Cash remaining | 989.29M | 960.85M | n/a | n/a | n/a | n/a |
| Runway (months of cash) | 18.0 | 12.9 | n/a | n/a | n/a | n/a |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Aug 22 | Eisenberg Glenn A | Common Stock | Sell | Dispose S | No | No | 254.879 | 1,500 | 382.32K | 52,158 |
| 3 Aug 22 | Eisenberg Glenn A | Common Stock | Sell | Dispose S | No | No | 254.259 | 19,338 | 4.92M | 53,658 |
| 3 Aug 22 | Eisenberg Glenn A | Common Stock | Sell | Dispose S | No | No | 253.265 | 11,262 | 2.85M | 72,996 |
| 3 Aug 22 | Eisenberg Glenn A | Common Stock | Option exercise | Acquire M | No | No | 146.59 | 11,600 | 1.7M | 84,258 |
| 3 Aug 22 | Eisenberg Glenn A | Common Stock | Option exercise | Acquire M | No | No | 168.49 | 9,100 | 1.53M | 72,658 |
| 3 Aug 22 | Eisenberg Glenn A | Common Stock | Option exercise | Acquire M | No | No | 130.6 | 11,400 | 1.49M | 63,558 |
| 3 Aug 22 | Eisenberg Glenn A | NQSO Common Stock | Option exercise | Dispose M | No | No | 146.59 | 11,600 | 1.7M | 0 |
| 3 Aug 22 | Eisenberg Glenn A | NQSO Common Stock | Option exercise | Dispose M | No | No | 168.49 | 9,100 | 1.53M | 0 |
| 3 Aug 22 | Eisenberg Glenn A | NQSO Common Stock | Option exercise | Dispose M | No | No | 130.6 | 11,400 | 1.49M | 0 |
| 1 Aug 22 | Peter J Wilkinson | Common Stock | Payment of exercise | Dispose F | No | No | 257.94 | 23 | 5.93K | 1,914.219 |
Institutional ownership, Q1 2022
86.9% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 990 |
| Opened positions | 80 |
| Closed positions | 115 |
| Increased positions | 354 |
| Reduced positions | 381 |
| 13F shares | Current |
|---|---|
| Total value | 21.23B |
| Total shares | 80.54M |
| Total puts | 208.1K |
| Total calls | 694K |
| Total put/call ratio | 0.3 |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 10.86M | $2.86B |
| BLK Blackrock | 9.58M | $2.53B |
| STT State Street | 4.3M | $1.13B |
| Wellington Management | 2.73M | $720.48M |
| TROW T. Rowe Price | 1.87M | $492.79M |
| Geode Capital Management | 1.86M | $490.66M |
| BAC Bank Of America | 1.78M | $468.87M |
| Dimensional Fund Advisors | 1.56M | $411.35M |
| FMR | 1.32M | $347.63M |
| JPM JPMorgan Chase & Co. | 1.27M | $335.05M |
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
administered, advertising, Boston, clearance, CLIA, CMS, contemplated, difficult, distribution, divert, diverting, draft, efficacy, effort, EU, Europe, exit, experience, FDA, focused, footprint, framework, grounded, guidance, infringement, Inova, instituted, IVDR, ix, labeling, LDT, legislation, legislative, letter, literature, lost, noncompliance, object, oversight, patent, pendency, percent, Permission, pharmacogenetic, Phase, policy, preclinical, proposed, quality, Ravgen, reaction, refrain, registration, satisfaction, scientific, sound, surveillance, systematic, timeline, Trademark, ultimate, unexpected, vandalism, vi, vii, viii, vitro, warning, Western, xi, xii
Removed:
conclusion, evaluate, initiated, invest, profitable, review, team, therapeutic
Financial reports
Current reports
8-K
Labcorp Announces 2022 Second Quarter Results
28 Jul 22
8-K
Regulation FD Disclosure
14 Jul 22
8-K
Labcorp Declares Quarterly Dividend
14 Jul 22
8-K
Labcorp to Speak at the Ubs 2022 Global Healthcare Conference
17 May 22
8-K
Submission of Matters to a Vote of Security Holders
13 May 22
8-K
Labcorp to Webcast Its Annual Meeting of Shareholders
4 May 22
8-K
Labcorp Announces 2022 First Quarter Results
28 Apr 22
8-K
Labcorp Initiates Quarterly Dividend
7 Apr 22
8-K
Regulation FD Disclosure
28 Mar 22
8-K
Labcorp Announces 2021 Fourth Quarter and Full-Year Results
10 Feb 22
Registration and prospectus
424B5
Prospectus supplement for primary offering
13 May 21
FWP
Free writing prospectus
12 May 21
424B5
Prospectus supplement for primary offering
12 May 21
424B5
Prospectus supplement for primary offering
19 Nov 19
FWP
Free writing prospectus
18 Nov 19
424B5
Prospectus supplement for primary offering
18 Nov 19
S-3ASR
Automatic shelf registration
12 Nov 19
424B5
Prospectus supplement for primary offering
15 Aug 17
FWP
Free writing prospectus
15 Aug 17
424B5
Prospectus supplement for primary offering
14 Aug 17
Proxies
DEFA14A
Additional proxy soliciting materials
31 Mar 22
DEFA14A
Additional proxy soliciting materials
2 Apr 21
DEFA14A
Additional proxy soliciting materials
1 Apr 20
DEFA14A
Additional proxy soliciting materials
29 Mar 19
DEFA14A
Additional proxy soliciting materials
5 Apr 18
DEF 14A
Definitive proxy
29 Mar 18
Other
SD
Conflict minerals disclosure
26 May 22
SD
Conflict minerals disclosure
28 May 21
SD
Conflict minerals disclosure
29 May 20
SD
Conflict minerals disclosure
30 May 19
SD
Conflict minerals disclosure
29 May 18
SD
Conflict minerals disclosure
29 May 17
UPLOAD
Letter from SEC
8 May 17
CORRESP
Correspondence with SEC
2 May 17
UPLOAD
Letter from SEC
23 Apr 17
CORRESP
Correspondence with SEC
16 Apr 17
Ownership
4
LABORATORY CORP OF AMERICA / GLENN A EISENBERG ownership change
5 Aug 22
4
LABORATORY CORP OF AMERICA / Peter J Wilkinson ownership change
3 Aug 22
4
LABORATORY CORP OF AMERICA / Brian J Caveney ownership change
14 Jun 22
4
LABORATORY CORP OF AMERICA / Mark S Schroeder ownership change
31 Mar 22
4
LABORATORY CORP OF AMERICA / der Vaart Sandra D van ownership change
31 Mar 22
4
LABORATORY CORP OF AMERICA / LANCE BERBERIAN ownership change
29 Mar 22
4
LABORATORY CORP OF AMERICA / Brian J Caveney ownership change
29 Mar 22
4
LABORATORY CORP OF AMERICA / GLENN A EISENBERG ownership change
29 Mar 22
4
LABORATORY CORP OF AMERICA / Paul R Kirchgraber ownership change
29 Mar 22
4
LABORATORY CORP OF AMERICA / Mark S Schroeder ownership change
29 Mar 22
Patents
Utility
Systems, methods, and media for laboratory benefit services
6 Jul 21
Inventors: Paul Conlin, Roberto Verrengia, Louis Engel
Utility
Enhanced Decision Support for Systems, Methods, and Media for Laboratory Benefit Services
24 Jun 21
Systems, methods, and media for laboratory benefit services are disclosed.
Utility
Enumeration of nucleic acids
27 Apr 21
Disclosed are methods and systems for enumeration of nucleic acids, including for the detection of rare events in a biological sample.
Utility
Compositions and Methods for Detection of Diseases Related to Exposure to Inhaled Carcinogens
21 Oct 20
Disclosed are compositions and methods to detect proteins associated with diseases associated with exposure to inhaled carcinogens.
Utility
Methods and Systems for Detecting Antibodies by Surface Plasmon Resonance
21 Oct 20
The present disclosure relates to a method for detection of an antibody or antibody fragment in a biological sample from a subject.
Transcripts
2022 Q2
Earnings call transcript
28 Jul 22
2022 Q1
Earnings call transcript
28 Apr 22
2021 Q4
Earnings call transcript
10 Feb 22
2021 Q3
Earnings call transcript
28 Oct 21
2021 Q2
Earnings call transcript
29 Jul 21
2021 Q1
Earnings call transcript
29 Apr 21
2020 Q4
Earnings call transcript
11 Feb 21
2020 Q3
Earnings call transcript
27 Oct 20
2020 Q2
Earnings call transcript
28 Jul 20
2020 Q1
Earnings call transcript
29 Apr 20
Reddit threads
Possible short on AUDJPY, trend is creating LL's and LH's on the 4H(first slide) and the trend looks exhausted on the daily time frame(third slide). What are your opinions? im always open for feedback!
8 Aug 22
ChartGalLori's Monday Pre-Game Notes for 8/8/22
8 Aug 22
Finding an edge
7 Aug 22
US30 (Short) trade this morning! Entry opportunity was seen in the H4 timeframe which was a double top on the 800 EMA and entry was taken on the M30 timeframe after the first LH was formed. Exit was 32670.47
4 Aug 22
SoFi is up with the influence of the bank charter.
3 Aug 22
What’s exactly “Swing high and Swing low” ?
3 Aug 22
ChartGalLori's Monday Pre-Game Notes for 8/1/22
1 Aug 22
Things you absolutely HAVE to do to develop a real edge:
29 Jul 22
USDCHF (Long). Entry triggers for both entries were the break of structure (BOS) of the previous LH/LL pushes. My exit is the estimated ADR for the day 💸
29 Jul 22
Daily Discussion Thread - July 28th, 2022
28 Jul 22